Autres langues Modalis Therapeutics Corporation

Actions

4883

JP3922600006

Marché Fermé - Japan Exchange Autres places de cotation 08:00:00 16/07/2024			Varia. 5j.	Varia. 1 janv.
70 ^JPY	0,00 %		0,00 %	-43,55 %

10/07	Modalis et GENIXCURE concluent un protocole d'entente pour une collaboration de recherche visant à développer des produits thérapeutiques de prochaine génération	CI
09/07	Modalis Therapeutics fixe le prix d'exercice de son nouveau programme d'options d'achat d'actions	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Modalis Therapeutics Partners Genixcure for Alzheimer's Treatment	10/07
Modalis and GENIXCURE Enter into Memorandum of Understanding for Research Collaboration to Develop Next-Generation Therapeutics	10/07
Modalis Therapeutics Sets Exercise Price for New Stock Option Program	09/07
Modalis Therapeutics to Reduce Headcounts at US Subsidiary to Lower Expenses by 35 to 40 Million Yen in Fiscal 2024	01/07
Modalis Therapeutics Issues Share Acquisition Rights to Directors, Employees	14/06
Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101: a First-in-Class Epigenome Editing approach for the Treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2-CMD)	07/05
Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101	07/05
Modalis Therapeutics Corporation to Present Data Supporting Development of Transformative Epigenome Editing Medicines for the Treatment of Muscular Dystrophy at the Global Cell & Gene Therapy Summit	30/04
Modalis Announces updated strategic plan and business consolidation of US operation	15/04
Modalis Announces Partnership with Ginkgo Bioworks	15/04
Modalis Therapeutics to See Reduced Expenses of 250 to 350 Million After Cutting Jobs	15/04
Modalis Announces Partnership with Ginkgo Bioworks	12/04
Modalis Therapeutics to Reduce Stated Capital and Capital Reserves	23/02
Japanese Shares Continue to Track Wall Street Higher as Investor Caution Ahead of US Rate Decision Caps Gains	13/12
Modalis Therapeutics, JCR Pharmaceuticals Form Drug Delivery Research Partnership	13/12
Modalis Therapeutics Corporation and JCR Pharmaceuticals Enter into Joint Research Agreement	13/12
Modalis and JCR Pharmaceuticals enter into joint research agreement	13/12
Modalis Therapeutics Corporation announced that it has received ¥505.320864 million in funding from Evolution Capital Management LLC	30/11
Modalis Therapeutics Corporation announced that it expects to receive ¥505.320864 million in funding from Evolution Capital Management LLC	07/11
Modalis Therapeutics Corporation cancelled the transaction announced on September 11, 2023	28/09/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Modalis Therapeutics Corporation

Actions

4883

JP3922600006

Autres langues

Filtres